Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2019
Reporting Period: Event date August 14, 2019; references Form 10-Q for the period ended June 30, 2019.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or debt. The report focuses on a specific listing standard violation:
- Stockholders' Equity: The company failed to maintain the minimum $2,500,000 stockholders' equity required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1).
- Source of Data: The deficiency was identified based on the company's Form 10-Q for the period ended June 30, 2019.
Material Changes
The primary material change is the receipt of a notification letter from The Nasdaq Stock Market LLC on August 14, 2019, stating that the company no longer meets the minimum stockholders' equity requirement. This notification has no immediate effect on the listing of the company's common stock.
Outlook, Risks, and Management Commentary
Compliance Plan: The company has until September 30, 2019, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days to demonstrate compliance.
Risks and Contingencies:
- There is no assurance the company will successfully regain compliance with the minimum stockholders' equity requirement.
- Failure to submit an acceptable plan or regain compliance within the allowed timeframe could result in delisting.
- The company retains the right to appeal a rejection of its compliance plan or a delisting determination to a Nasdaq Hearings Panel.
Management Action: The company is currently evaluating options to regain compliance and intends to timely submit a plan.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the period ended June 30, 2019.
- Monitor the submission of the compliance plan by the September 30, 2019 deadline.
- Track any subsequent announcements regarding Nasdaq's acceptance of the plan or the granting of an extension.
- Review the company's capital raising activities or balance sheet adjustments intended to restore equity levels.